reports
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Griffon Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 24 November 2025 in which we reassessed the appropriateness of the ratings in the conte...
Avalo Therapeutics Announces Inducement Grants to New Employees Under ...
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock (the “Options”) as indu...
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
RGP RESOURCES CONNECTION INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FLDM FLUIDIGM
FDS FACTSET RESEARCH SYSTEMS INC.
AROW ARROW FINANCIAL CORP.
GAM GENERAL AMERICAN INVESTORS CO. INC.
WHF WHITEFIELD
FMC FMC CORPORATION
LPX LOUISIANA-PACIFIC CORPORATION
SXC SUNCOKE ENERGY INC.
ITGR INTEGER HOLDINGS CORPORATION
ICHR ICHOR HOLDINGS LTD.
KREF KKR REAL ESTATE FINANCE TRUST
NWPP NEW PEOPLES BANKSHARES INC.
REZI RESIDEO TECHNOLOGIES
WU INC.
AEYE THE WESTERN UNION COMPANY
AMCR AUDIOEYE INC
BW AMCOR PLC
THRY BABCOCK & WILCOX ENTERPRISES
UTZ THRYV HOLDINGS
OPEN UTZ BRANDS INC (A)
ACVA OPENDOOR TECHNOLOGIES INC.
UPST ACV AUCTIONS INC.
FRSH UPSTART HOLDINGS
CLVT FRESHWORKS INC.
TRDA CLARIVATE PLC
SG ENTRADA THERAPEUTICS INC
TBBK SWEETGREEN INC
BLND THE BANCORP
CRVO INC.
NEXT ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
SPRU CERVOMED INC
LAW NEXTSOURCE MATERIALS INC.
MRAI SPRUCE POWER HOLDING CORP
BNTC CS DISCO INC
GF MARPAI
HYMC INC.
SENS BENITEC BIOPHARMA INC
BATRK THE NEW GERMANY FUND
INC.
HYCROFT MINING HOLDING CORPORATION
SENSEONICS HOLDINGS INC.
LIBERTY MEDIA CORP
- Jonathan Moreland
RGP RESOURCES CONNECTION INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FAST FASTENAL COMPANY
TZOO TRAVELZOO
ITGR INTEGER HOLDINGS CORPORATION
BX THE BLACKSTONE GROUP L.P.
REZI RESIDEO TECHNOLOGIES
AEYE INC.
BW AUDIOEYE INC
PNTG BABCOCK & WILCOX ENTERPRISES
MRVI PENNANT GROUP
UPST MARAVAI LIFESCIENCES HOLDINGS
NEXT UPSTART HOLDINGS
CLVT NEXT CAPITAL
OGN CLARIVATE PLC
MYPS ORGANON & CO
FRST PLAYSTUDIOS INC
RBA PRIMIS FINANCIAL CORP
CRVO RITCHIE BROS AUCTIONEERS INC.
GAM CERVOMED INC
MDRR GENERAL DE ALQUILER DE MAQUINARIA
SENS MEDALIST DIVERSIFIED REIT INC.
BATRK SENSEONICS HOLDINGS INC.
LIBERTY MEDIA CORP
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
35G GENPACT LIMITED
EXPE EXPEDIA GROUP INC.
CRK COMSTOCK RESOURCES INC.
AXTI AXT INC.
ALB ALBEMARLE CORPORATION
ACRE ARES COMMERCIAL REAL ESTATE
AGO ASSURED GUARANTY LTD.
HRTG HERITAGE INSURANCE HOLDINGS INC.
DRH DIAMONDROCK HOSPITALITY COMPANY
ELY CALLAWAY GOLF COMPANY
FLGT FULGENT GENETICS
DK DELEK US HOLDINGS INC
TALO TALOS ENERGY INC.
LASR NLIGHT
GLOB GAZIT-GLOBE LTD.
ARVN ARVINAS HOLDING
PLMR PALOMAR HOLDINGS
BW BABCOCK & WILCOX ENTERPRISES
TXG 10X GENOMICS INC CLASS A
PGNY PROGYNY
AMPY AMPLIFY ENERGY
EOSE EOS ENERGY ENTERPRISES INC (A)
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
DOCN DIGITALOCEAN HLDGS INC
DSGN DESIGN THERAPEUTICS INC
FIGS FIGS INC
YOU ONTO INNOVATION INC.
PPTA CLEAR SECURE INC
AMPX PERPETUA RESOURCES CORP
OS AMPRIUS TECHNOLOGIES INC
SNDK ONESTREAM INC
CSIOX SANDISK CORP
BALY CATALYST PERINI STRATEGIC INCOM ORD
HOII BALLY'S CORPORATION
REX HOOD GROWTH & INCOME ETF
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
ATNI ATN INTERNATIONAL INC.
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
LGND LIGAND PHARMACEUTICALS INCORPORATED
PLNT PLANET FITNESS INC. CLASS A
HOO HERBALIFE NUTRITION LTD.
COLL COLLEGIUM PHARMACEUTICAL INC.
AMBA AMBARELLA INC.
SKY SKYLINE CHAMPION CORPORATION
NYT NEW YORK TIMES COMPANY CLASS A
DLX DELIGNIT AG
MTSI MACOM TECHNOLOGY SOLUTIONS HOLDINGS INC.
NOMDN NOMAD FOODS LTD.
LILA LIBERTY LATIN AMERICA A
DUBA DRDGOLD LTD. ADS
BW BABCOCK & WILCOX ENTERPRISES
SITM SITIME
LZ LEGALZOOM.COM INC
DERM JOURNEY MEDICAL CORP
COHR COHERENT CORP
GPCR STRUCTURE THERAPEUTICS
SBGI SINCLAIR INC
FBYD FALCONS BEYOND GLOBAL INC
MRX MAREX GROUP PLC
LB LANDBRIDGE COMPANY LLC
ORKA ORUKA THERAPEUTICS INC
ECG_w EVERUS CONSTRUCTION GROUP INC.
BKTI BK TECHNOLOGIES CORP
RAL RALLIANT CORP
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Re...
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team with key appointments in business development and human resourcesCash and short-term investments of approximately $112 million as of September 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechno...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Second Annual Healthcare Innovation ConferenceFireside ChatNovember 10, 2025, at 4:00 pm ET Stifel 2025 Healthcare ConferenceFireside ChatNovember 12, 2025, at 2:40 pm ET TD Cowen 1st Immunology & Inflamm...
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS...
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company has completed enrollment in its Phase 2 LOTUS trial of AVTX-009 in adults with hidradenitis suppurativa (HS). The LOTUS trial exceeded target enrollment of 222 patients with approximately 250 patients enro...
Avalo Therapeutics Expands Leadership Team with Key Appointments in Bu...
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. “We are delighted to welcome Taylor and Ashley to Aval...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare ConferenceFireside ChatSeptember 3, 2025, at 2:10 pm ET H.C.Wainwright 27th Annual Global Investment ConferencePresentationSeptember 9, 2025, at 2:30 pm ET Stifel 2025 Virtual Immunology and...
Avalo Reports Second Quarter 2025 Financial Results and Recent Busines...
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately $113 million as of June 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, t...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences: HCW Annual Inflammation & Immunology Virtual ConferenceFireside ChatJune 30, 2025, at 11:00 am ET BTIG Virtual Biotechnology Conference 20251x1sJuly 29-30, 2025 Live webcasts and replays, when available, can be found under "News / Events" in the Investors secti...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board o...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. “We are pleased to welcome Dr. Jain to Avalo’s Board of Directors,” said Michael Heffernan, Chairman of the Board. “Rita’s extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biophar...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June. Jefferies Global Healthcare Conference 2025, New YorkFireside ChatJune 4, 2025, at 7:35 am ET Oppenheimer Innovators in I&I Summit, New YorkPanelist: “Dermatology: AA, HS, PSO”June 25, 2025, at 10am ET Live webcasts and replays, when a...
Avalo Reports First Quarter 2025 Financial Results and Recent Business...
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway into 2027, with optionality to extend into 2028 WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and...
Avalo Therapeutics to Participate in The Citizens Life Sciences Confer...
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at . The...
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. “We are thrilled to welcome Michael to Avalo’s Board of Directors during...
Avalo Reports 2024 Financial Results and Recent Business Updates
Avalo Reports 2024 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.